Table 1. Baseline Characteristics of Eligible Studies.

Author	Year	Country	Ethnicity	Chemotherapy	TNM Stage	Num	Age	Male
Butkiewicz D	2012	Poland	Caucasian	radiotherapy+chemotherapy	III-IV 90%	250	<62, 48%	65%
Chen X	2011	China	Asian	cisplatin/carboplatin+gemcitabine/vinorelbine/paclitaxel/docetaxel	IV66.8%/III B 33.2%	355	60(32–78)	69.9%
de las Peñas R	2005	Italy	Caucasian	cisplatin+gemcitabine	III B 17%/IV83%	135	62 (31–81)	92.6%
Joerger M	2011	Netherlands	Mixed	gemcitabine+cisplatin/carboplatin	IV69%/IIIB 31%	137	59.7(37–79)	56%
Ke HG	2012	China	Asian	cisplatin/gemcitabine/docetaxel/vinorelbine/paclitaxel	/IV39.1%/III 26.6%	460	59.5±3.5	72.6%
Liao WY †	2012	China	Asian	gemcitabine/bevacizumab+cisplatin/carboplatin/oxaliplatin	IV84%/III B 16%	62	57(36–78)	56.5%
Ludovini V	2011	Italy	Caucasian	cisplatin+gemcitabine/vinorelbine/taxol/gemcitabine alone	IV76%/III B 24%	192	63(25–81)	74.0%
Osawa K	2012	Japan	Asian	NA	III-IV 20.2%	99	66.3±9.3	65.7%
Provencio M	2012	Spain	Caucasian	cisplatin+vinorelbine	IV83%/III B 17%	180	62(39–78)	87.2%
Ren S	2011	China	Asian	cisplatin+gemcitabine/docetaxel/vinorelbine/paclitaxel	IV67.4%/III B 32.6%	340	60(30–78)	68.2%
Ren SX	2009	Chian	Asian	cisplatin/carboplatin+gemcitabine/vinorelbine/paclitaxel	IV69.9%/IIIB30.1%	130	61(30–78)	56.9%
Xu C	2011	China	Asian	cisplatin+gemcitabine/docetaxel/vinorelbine/paclitaxel	advanced	130	62(28–83)	69.2%
Yin M	2011	China	Asian	radiotherapy+chemotherapy	III-IV 82.5%	228	63(35–88)	54.8%
Zhou C	2010	China	Asian	cisplatin+gemcitabine/vinorelbine/paclitaxel	IV69.2%/III B 30.8%	130	61(30–78)	56.9%

Age is presented as median and range or mean±standard deviation; † data was extracted from training set.